MedReleaf Corp. announces it will collaborate with the Canadian Football League Alumni Association (CFLAA) in conducting an observational study on the benefits of medical cannabis in treating chronic pain and related ailments in retired professional athletes.
“We are excited to collaborate with the CFL Alumni Association on this significant observational study with legends in the Canadian athletic arena,” says Neil Closner, MedReleaf CEO. “Through ongoing research, our understanding of the benefits of medical cannabis has grown significantly and we welcome the opportunity to apply our expertise in validating new patient therapies and contributing to positive patient outcomes for this exceptional group of former athletes.”
MedReleaf and the CFLAA recognize the opportunity to collaborate on this important study which will bring greater awareness to the potential health benefits of using medical cannabis in the treatment of ailments that include chronic pain. The joint observational study is scheduled to begin in the summer of 2018 with volunteer CFLAA member participants.
“The CFLAA has always sought to make a difference by providing support to our alumni, many of whom experienced medical challenges following their athletic careers,” says Leo Ezerins, CFLAA Executive Director. “In collaborating with MedReleaf we hope to gain further insight into the benefits of medical cannabis in managing chronic pain – insight that could be invaluable to our almost 2,000 alumni members.”
MedReleaf is an R&D-driven company devoted providing top-quality cannabis. They have two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario Canada, and a third facility currently in development. MedReleaf serves the therapeutic needs of patients seeking safe, consistent and effective medical cannabis for recreational and medicinal use.